Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$65.83−2.46 (-3.60%)
Close on Nov 19, 2026Market cap $16.06BP/E 19.7Yield –
Exelixis net income
Net income is the profit left for shareholders after every expense, interest and tax.
Exelixis's net income for the twelve months ending Oct 2, 2026 was $885.14M, up 30.6% year over year. For fiscal 2025 it was $782.57M, up 50.1% from the year before. The highest annual figure on record is $782.57M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $782.57M | +50.1% |
| FY2024 | Jan 3, 2025 | $521.27M | +150.9% |
| FY2023 | Dec 29, 2023 | $207.77M | +14.0% |
| FY2022 | Dec 30, 2022 | $182.28M | -21.1% |
| FY2021 | Dec 31, 2021 | $231.06M | +106.7% |
| FY2020 | Jan 1, 2021 | $111.78M | -65.2% |
| FY2019 | Jan 3, 2020 | $321.01M | -53.5% |
| FY2018 | Dec 28, 2018 | $690.07M | +347.4% |
| FY2017 | Dec 29, 2017 | $154.23M | – |
| FY2016 | Dec 31, 2016 | -$70.22M | – |
| FY2015 | Dec 31, 2015 | -$161.74M | – |
| FY2014 | Dec 31, 2014 | -$261.30M | – |
| FY2013 | Dec 31, 2013 | -$238.19M | – |
| FY2012 | Dec 31, 2012 | -$145.34M | -292.0% |
| FY2011 | Dec 31, 2011 | $75.70M | – |
| FY2010 | Dec 31, 2010 | -$92.33M | – |
| FY2009 | Dec 31, 2009 | -$135.22M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $218.10M | +12.7% |
| Q2 FY2026 | Jul 3, 2026 | $212.05M | +14.7% |
| Q1 FY2026 | Apr 3, 2026 | $210.47M | +31.9% |
| Q4 FY2025 | Jan 2, 2026 | $244.53M | +74.8% |
| Q3 FY2025 | Oct 3, 2025 | $193.58M | +64.1% |
| Q2 FY2025 | Jul 4, 2025 | $184.85M | -18.3% |
| Q1 FY2025 | Apr 4, 2025 | $159.62M | +327.7% |
| Q4 FY2024 | Jan 3, 2025 | $139.86M | +63.5% |
| Q3 FY2024 | Sep 27, 2024 | $117.97M | +11232.7% |
| Q2 FY2024 | Jun 28, 2024 | $226.12M | +178.5% |
| Q1 FY2024 | Mar 29, 2024 | $37.32M | -6.8% |
| Q4 FY2023 | Dec 29, 2023 | $85.52M | – |
| Q3 FY2023 | Sep 29, 2023 | $1.04M | -98.6% |
| Q2 FY2023 | Jun 30, 2023 | $81.18M | +14.9% |
| Q1 FY2023 | Mar 31, 2023 | $40.03M | -41.6% |
| Q4 FY2022 | Dec 30, 2022 | -$30.17M | -131.7% |
| Q3 FY2022 | Sep 30, 2022 | $73.21M | +91.6% |
| Q2 FY2022 | Jul 1, 2022 | $70.67M | -26.5% |
| Q1 FY2022 | Apr 1, 2022 | $68.57M | +4183.1% |
| Q4 FY2021 | Dec 31, 2021 | $95.17M | +235.2% |
| Q3 FY2021 | Oct 1, 2021 | $38.20M | – |
| Q2 FY2021 | Jul 2, 2021 | $96.09M | +43.8% |
| Q1 FY2021 | Apr 2, 2021 | $1.60M | -96.7% |
| Q4 FY2020 | Jan 1, 2021 | $28.39M | -58.7% |
| Q3 FY2020 | Oct 2, 2020 | -$32.04M | -132.9% |
| Q2 FY2020 | Jul 3, 2020 | $66.82M | -15.5% |
| Q1 FY2020 | Apr 3, 2020 | $48.61M | -35.8% |
| Q4 FY2019 | Jan 3, 2020 | $68.74M | -80.9% |
| Q3 FY2019 | Sep 27, 2019 | $97.45M | -23.0% |
| Q2 FY2019 | Jun 28, 2019 | $79.04M | -9.7% |
| Q1 FY2019 | Mar 29, 2019 | $75.78M | -34.6% |
| Q4 FY2018 | Dec 28, 2018 | $360.09M | +835.6% |
| Q3 FY2018 | Sep 28, 2018 | $126.63M | +55.6% |
| Q2 FY2018 | Jun 29, 2018 | $87.49M | +395.5% |
| Q1 FY2018 | Mar 30, 2018 | $115.86M | +593.8% |
| Q4 FY2017 | Dec 29, 2017 | $38.49M | +9.6% |
| Q3 FY2017 | Sep 30, 2017 | $81.38M | – |
| Q2 FY2017 | Jun 30, 2017 | $17.66M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $35.12M | – |
See a number that looks wrong?